Strategic Wealth Partners Ltd. Raises Stock Position in Eli Lilly and Company (NYSE:LLY)

Strategic Wealth Partners Ltd. raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 4.0% during the third quarter, Holdings Channel reports. The firm owned 11,942 shares of the company’s stock after buying an additional 455 shares during the quarter. Eli Lilly and Company makes up approximately 1.0% of Strategic Wealth Partners Ltd.’s portfolio, making the stock its 22nd biggest position. Strategic Wealth Partners Ltd.’s holdings in Eli Lilly and Company were worth $10,580,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in LLY. Capital Planning LLC bought a new stake in shares of Eli Lilly and Company during the 1st quarter valued at $262,000. CHURCHILL MANAGEMENT Corp bought a new stake in shares of Eli Lilly and Company during the 1st quarter valued at $6,916,000. M&G Plc bought a new stake in shares of Eli Lilly and Company during the 1st quarter valued at $8,896,000. HighPoint Advisor Group LLC bought a new stake in shares of Eli Lilly and Company during the 4th quarter valued at $9,878,000. Finally, Leo Wealth LLC bought a new stake in shares of Eli Lilly and Company during the 4th quarter valued at $3,355,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Up 1.7 %

Eli Lilly and Company stock opened at $913.72 on Wednesday. The firm has a 50 day moving average of $901.94 and a 200 day moving average of $849.30. The firm has a market capitalization of $868.40 billion, a price-to-earnings ratio of 134.57, a P/E/G ratio of 2.78 and a beta of 0.42. Eli Lilly and Company has a 12-month low of $547.61 and a 12-month high of $972.53. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The company had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. As a group, research analysts predict that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on LLY. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Barclays upped their price target on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. JPMorgan Chase & Co. upped their price target on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th. Finally, Berenberg Bank upped their price target on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $977.35.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.